Along with the news of the abrupt resignation of Pfizer's former CEO Jeffrey Kindler, the drug giant has now been dragged into the red-hot WikiLeaks controversy. Oh boy, buckle your seatbelts ...
December 13, 2010 at 12:00 AM
1 minute read
Former Pfizer Inc. CEO Jeffrey Kindler’s abrupt resignation on Dec. 5 came just in time to give the feds what they wanted: A new leadership structure at the drug giant.
While accepting Kindler’s resignation, the board of directors suddenly reversed its longstanding stance on corporate structure — announcing that Kindler’s replacement would hold the CEO job only, and that a new chairman of the board would be named later.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
This event shines a spotlight on the individuals, teams, projects and organizations that are changing the financial industry.
CORE RESPONSIBILITIES AND TASKS:(1) Tasks and responsibilities include:Reviewing and negotiating commercial agreements for internal business...
Boutique midtown Manhattan law firm specializing in sophisticated real estate litigation & representation of commercial and residential ...
Description: Fox Rothschild has an opening in the Boston, MA office for a Litigation Associate with 3 to 5 years of experience. The ideal ca...
Predictive reporting, trend analysis, peer guidance and a practical playbook to help general counsels succeed in their increasingly high stakes roles as risk managers and corporate strategists
